Before Translating Extracellular Vesicles into Personalized Diagnostics and Therapeutics: What We Could Do
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.4c00185 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Chi-An Cheng. Beteiligte Einrichtung: School of Pharmacy, College of Medicine, National Taiwan University, Taipei 10050, Taiwan. Hauptthemen laut MEDLINE: Extracellular Vesicles, Precision Medicine. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Taiwan University, National Science and Technology Council, Ministry of Education, Taiwan.
Abstract (Originalsprache)
Extracellular vesicle (EV) research is rapidly advancing from fundamental science to translational applications in EV-based personalized therapeutics and diagnostics. Yet, fundamental questions persist regarding EV biology and mechanisms, particularly concerning the heterogeneous interactions between EVs and cells. While we have made strides in understanding virus delivery and intracellular vesicle transport, our comprehension of EV trafficking remains limited. EVs are believed to mediate intercellular communication through cargo transfer, but uncertainties persist regarding the occurrence and quantification of EV-cargo delivery within acceptor cells. This ambiguity is crucial to address, given the significant translational impact of EVs on therapeutics and diagnostics. This perspective article does not seek to provide exhaustive recommendations and guidance on EV-related studies, as these are well-articulated in position papers and statements by the International Society for Extracellular Vesicles (ISEV), including the 'Minimum Information for Studies of Extracellular Vesicles' (MISEV) 2014, MISEV2018, and the recent MISEV2023. Instead, recognizing the multilayered heterogeneity of EVs as both a challenge and an opportunity, this perspective emphasizes novel approaches to facilitate our understanding of diverse EV biology, address uncertainties, and leverage this knowledge to advance EV-based personalized diagnostics and therapeutics. Specifically, this perspective synthesizes current insights, identifies opportunities, and highlights exciting technological advancements in ultrasensitive single EV or "digital" profiling developed within the author's multidisciplinary group. These newly developed technologies address technical gaps in dissecting the molecular contents of EV subsets, contributing to the evolution of EVs as next-generation liquid biopsies for diagnostics and providing better quality control for EV-based therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, College of Medicine, National Taiwan University, Taipei 10050, Taiwan.
ORCID-Profile: Chi-An Cheng
Förderung
- National Taiwan University
- National Science and Technology Council
- Ministry of Education, Taiwan
Zitieren
APA
Cheng, C. A. (2024). Before Translating Extracellular Vesicles into Personalized Diagnostics and Therapeutics: What We Could Do. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00185
Vancouver
Cheng CA. Before Translating Extracellular Vesicles into Personalized Diagnostics and Therapeutics: What We Could Do. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00185
BibTeX
@article{Cheng2024,
author = {Cheng, Chi-An},
title = {Before Translating Extracellular Vesicles into Personalized Diagnostics and Therapeutics: What We Could Do},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.4c00185}
}
EUVIMED